ArticleAntimicrobial agents and chemotherapy2013
Antibacterial activity of eravacycline (TP-434), a novel fluorocycline, against hospital and community pathogens.
Article in Antimicrobial agents and chemotherapy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 118 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
118 citing papers in PubMed, 1 synthesis or guideline pooled it, 225 citations in OpenAlex.
- Resistance of Gram-Negative Bacteria to Eravacycline: A Systematic Review of Data from In Vitro Studies.Pathogens (Basel, Switzerland) · 2025Pooled it
- Randomized, Double-Blind, Placebo-Controlled Studies of the Safety and Pharmacokinetics of Single and Multiple Ascending Doses of Eravacycline.Antimicrobial agents and chemotherapy · 2018Trial
- Phase 2, randomized, double-blind study of the efficacy and safety of two dose regimens of eravacycline versus ertapenem for adult community-acquired complicated intra-abdominal infections.Antimicrobial agents and chemotherapy · 2014Trial
- Phase I, open-label, safety and pharmacokinetic study to assess bronchopulmonary disposition of intravenous eravacycline in healthy men and women.Antimicrobial agents and chemotherapy · 2014Trial
- The Role of Pyrrolidine in Antibacterial Drug Discovery: Clinically Approved Antibiotics, Novel Derivatives, and Future Perspectives.International journal of molecular sciences · 2026Review
- Eravacycline and omadacycline Rescue multidrug-resistant Elizabethkingia anophelis: Triple-Model evaluation across in Vitro, Galleria mellonella, and murine bacteremia systems.Journal of advanced research · 2026Article
- Eravacycline as a Novel Option for Treating Multidrug-Resistant Gram-Negative and Gram-Positive Bacterial Infections: A Narrative Review.Journal of clinical medicine · 2026Review
- Article
- Multidrug-resistant Acinetobacter spp. bloodstream infections in hematologic patients: clinical characteristics, genomic features, and eravacycline-based combination therapy.BMC infectious diseases · 2026Article
- Beyond β-Lactams: Defining the Role of Eravacycline in Multidrug-Resistant and Metallo-β-Lactamase-Producing Infections.Antibiotics (Basel, Switzerland) · 2026Review
- Emergence and dissemination of extensively drug-resistant ST307Microbial genomics · 2026Article
- Eravacycline: From broad-spectrum coverage to novel clinical applications.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2026Review
- Evaluation of eravacycline susceptibility testing by MIC test strip and disk diffusion against broth microdilution in carbapenem-resistant Enterobacterales.Frontiers in cellular and infection microbiology · 2026Article
- Incidence and characteristics of eravacycline-associated increase in serum bilirubin levels: a retrospective study.Frontiers in pharmacology · 2026Article
- Real-world effectiveness and predictors of treatment failure for eravacycline in patients withFrontiers in cellular and infection microbiology · 2026Article
- Eravacycline use in immunocompromised patients: multicenter evaluation of timely versus late initiation on clinical outcomes.Microbiology spectrum · 2025Observational
- Effective Management of Carbapenem-Resistant Enterobacterales Bloodstream Infection with Organ Dissemination in Prolonged Severe Agranulocytosis Patients with Hematological Malignancy Through Combination Therapies Including Eravacycline.Infectious diseases and therapy · 2025Article
- Covalent Irreversible Inhibitors of Tetracycline Destructases.ACS infectious diseases · 2025Article
- In vitro synergistic effect and mutant prevention concentration of eravacycline alone or in combination with various antibiotics against OXA-48 producing enterobacterales.The Journal of antibiotics · 2025Article
- Rare or Unusual Non-Fermenting Gram-Negative Bacteria: Therapeutic Approach and Antibiotic Treatment Options.Antibiotics (Basel, Switzerland) · 2025Review
58 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Eravacycline (TP-434 or 7-fluoro-9-pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline) is a novel fluorocycline that was evaluated for antimicrobial activity against panels of recently isolated aerobic and anaerobic Gram-negative and Gram-positive bacteria. Eravacycline showed potent broad-spectrum activity against 90% of the isolates (MIC90) in each panel at concentrations ranging from ≤0.008 to 2 μg/ml for all species panels except those of Pseudomonas aeruginosa and Burkholderia cenocepacia (MIC90 values of 32 μg/ml for both organisms). The antibacterial activity of eravacycline was minimally affected by expression of tetracycline-specific efflux and ribosomal protection mechanisms in clinical isolates. Furthermore, eravacycline was active against multidrug-resistant bacteria, including those expressing extended-spectrum β-lactamases and mechanisms conferring resistance to other classes of antibiotics, including carbapenem resistance. Eravacycline has the potential to be a promising new intravenous (i.v.)/oral antibiotic for the empirical treatment of complicated hospital/health care infections and moderate-to-severe community-acquired infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.